comparemela.com

Short Primary Endpoint News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Rationale for Shorter Endpoints in Biosimilar Clinical Trials

Rishi P. Singh, MD; and Michael A. Klufas, MD, comment on the reasoning behind a shorter primary end point for biosimilar studies.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.